Zolmitriptan and human aggression: interaction with alcohol.
BACKGROUND
The serotonin 1(B/D) (5-HT1(B/D)) receptor has shown potential as a target for decreasing aggression. The 5-HT1(B/D) agonist zolmitriptan's ability to reduce aggressive behavior in humans and its interaction with the well-known aggression-enhancing drug alcohol were examined.


OBJECTIVE
Our objective was to investigate zolmitriptan's potential to modify human aggression in a laboratory paradigm across a range of alcohol doses. Alcohol has been consistently associated with aggression and violence, thus we hoped to expand current understanding of alcohol's role in aggressive behavior via manipulation of the serotonin (5-HT) system.


METHODS
Eleven social drinkers, seven male, were recruited to participate in a research study lasting 3-4 weeks. Aggression was measured using the point-subtraction aggression paradigm (PSAP), a laboratory model widely used in human aggression studies. Subjects were administered 5-mg zolmitriptan and placebo capsules along with alcohol doses of 0.0, 0.4 and 0.8 g/kg in a within-subject, counterbalanced dosing design. Data were analyzed as the ratio of aggressive/monetary-earning responses, to account for possible changes in overall motor function due to alcohol.


RESULTS
There was a significant alcohol by zolmitriptan interaction on the aggressive/monetary response ratio. Specifically, compared to placebo, zolmitriptan decreased the aggressive/monetary ratio at the 0.4- and 0.8-g/kg alcohol doses.


CONCLUSIONS
A 5-mg dose of zolmitriptan effectively reduced alcohol-related aggression in an acute dosing protocol, demonstrating an interaction of 5-HT and alcohol in human aggressive behavior.
Gowin
Joshua L
JL
Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center Houston, Houston, TX, USA.
Swann
Alan C
AC
Moeller
F Gerard
FG
Lane
Scott D
SD
D000328:Adult; D000374:Aggression / Q000187:drug effects*; D001944:Breath Tests / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D000431:Ethanol / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D023303:Oxazolidinones / Q000494:pharmacology*; D010919:Placebos; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D014363:Tryptamines / Q000494:pharmacology*
D023303:Oxazolidinones; D010919:Placebos; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; D000431:Ethanol
Arch Gen Psychiatry. 1998 Nov;55(11):989-94
9819067
Fundam Clin Pharmacol. 2007 Jun;21(3):265-72
17521295
Psychopharmacology (Berl). 2004 Nov;176(3-4):451-8
15160265
J Stud Alcohol. 1996 Mar;57(2):178-86
8683967
Psychopharmacology (Berl). 1999 Oct;146(4):440-6
10550494
Cell Mol Neurobiol. 2008 Nov;28(7):1017-25
18425575
Psychopharmacology (Berl). 2002 Jan;159(3):266-74
11862359
Psychopharmacology (Berl). 2001 Sep;157(2):131-41
11594437
Psychopharmacology (Berl). 2001 Aug;156(4):477-80
11498726
J Stud Alcohol. 1985 Jul;46(4):321-8
4033132
Alcohol Alcohol. 1998 Jan-Feb;33(1):47-54
9539177
Psychopharmacology (Berl). 1996 Jul;126(2):97-103
8856827
Sci Signal. 2008 Jul 15;1(28):re7
18632551
Psychopharmacology (Berl). 1995 Jun;119(4):353-60
7480513
Alcohol Clin Exp Res. 1998 Dec;22(9):1898-902
9884131
Alcohol Alcohol. 1991;26(1):71-9
1854375
Psychiatry Res. 1979 Oct;1(2):131-9
95232
J Subst Abuse. 2001;13(4):563-81
11775083
Clin Psychol Rev. 2009 Aug;29(6):506-18
19573964
Psychopharmacology (Berl). 1999 Oct;146(4):473-81
10550498
Alcohol Res Health. 2001;25(1):20-31
11496963
Arch Gen Psychiatry. 1979 Feb;36(2):224-7
420544
Alcohol Clin Exp Res. 2003 Dec;27(12):1944-54
14691382
Psychol Rep. 1966 Feb;18(1):163-94
5908477
Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58
5554941
Recent Dev Alcohol. 1997;13:227-43
9122497
Eur J Pharmacol. 2005 Dec 5;526(1-3):207-17
16310769
Psychopharmacology (Berl). 2004 Feb;172(1):68-77
14647967
Psychopharmacology (Berl). 1999 Oct;146(4):391-9
10550489
Neuropsychopharmacology. 2008 Nov;33(12):2888-99
18305458
Psychopharmacology (Berl). 2002 Oct;163(3-4):434-58
12373445
Behav Cogn Neurosci Rev. 2003 Sep;2(3):179-97
15006292
Clin Drug Investig. 2005;25(3):199-208
17523769
Psychol Sci. 2009 Jun;20(6):714-20
19422623
Psychol Bull. 1996 Jul;120(1):60-82
8711017
Psychoneuroendocrinology. 2008 Aug;33(7):897-908
18657368
Eur J Pharmacol. 2005 Dec 5;526(1-3):51-64
16325649
Drug Alcohol Depend. 1997 Jun 6;46(1-2):95-103
9246557
Psychoneuroendocrinology. 2009 May;34(4):561-70
19054624
J Clin Psychopharmacol. 2003 Jun;23(3):269-80
12826989
Trends Pharmacol Sci. 1992 Feb;13(2):69-75
1561716
Alcohol Clin Exp Res. 2009 Apr;33(4):581-90
19183141
Exp Clin Psychopharmacol. 1997 Feb;5(1):28-38
9234037
J Psychiatr Res. 2009 Aug;43(12):1036-48
19232640
J Pharmacokinet Pharmacodyn. 2006 Feb;33(1):75-91
16402287
Am J Psychiatry. 2008 Apr;165(4):429-42
18346997
Neuroscience. 1994 Jan;58(1):167-82
8159291
Exp Clin Psychopharmacol. 2009 Jun;17(3):154-64
19586230
Violence Vict. 2007;22(1):95-103
17390565
Psychopharmacology (Berl). 2001 Sep;157(3):221-7
11605076
Exp Clin Psychopharmacol. 2009 Dec;17(6):445-55
19968409
Am J Psychiatry. 2001 Nov;158(11):1783-93
11691682
Psychopharmacology (Berl). 1999 Feb;142(2):144-8
10102766
Psychopharmacology (Berl). 2006 May;185(4):441-50
16550387
Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):899-911
18028032
J Pers Soc Psychol. 1976 Nov;34(5):938-41
993987
J Stud Alcohol. 2005 Nov;66(6):815-24
16459943
Psychiatry Res. 2007 Jan 15;149(1-3):201-13
17129610
Neuropsychopharmacology. 1999 Aug;21(2):238-46
10432472
Adv Exp Med Biol. 1999;467:57-65
10721038
Psychol Med. 1996 Mar;26(2):323-31
8685288
Life Sci. 2004 Nov 19;76(1):1-8
15501475
Psychopharmacology (Berl). 2008 Dec;201(2):237-48
18688602
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):129-39
14687867
Biol Psychiatry. 1997 Mar 1;41(5):514-22
9046983
Biol Psychiatry. 2007 Apr 15;61(8):974-8
17217931